Trial: 202002058

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy



Principal Investigator

Hayashi, Robert

Disease Site

Leukemia, other; Lymphoid Leukemia; Non-Hodgkin Lymphoma

Learn more about this study at: